Wednesday, 12 April 2017 12:00-1:30pm ET
Sponsored by:
With the implementation of PDUFA VI, the FDA is setting into motion a series of regulatory actions that will guide the future of drug development – and ultimately the success of approval and market access.
A key area of focus is making sure patients are involved in the overall process to review and approve new treatments. With the increasing power of the patient voice, it will be essential that developers demonstrate that their drugs are valuable to patients by integrating the patient perspective into early-stage drug development.
Those who are successful in answering this question will be better positioned to mitigate and avoid the risk of research gaps and unanswered needs when a compound gets to Phase III. They will also be better aligned with future FDA guidances.
Learning Level:
Basic: Content is introductory in nature and requires no requisite knowledge or experience to grasp concepts and related exercises. Basic educational activities are meant to establish a foundation of knowledge and/or competence that will be expanded upon in practice or in higher level activities.
Regulatory Affairs Professionals Society (RAPS)5635 Fishers Lane, Suite 400Rockville, Maryland 20852
raps@raps.org+1 301 770 2920
JoinMy RAPS DashboardLearn More
About UsTerms of UsePrivacy Policy